Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCN5 recombinant protein
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
CCN5 recombinant protein (also known as rh-CCN5 or WISP2) is a recombinant human protein derived from the CCN family of matricellular proteins, encoded by the WISP2/CCN5 gene. It is currently a research-stage compound with no approved brand name or single developing pharmaceutical company, primarily available as a research reagent from multiple suppliers. Preclinical studies have investigated its potential in promoting pancreatic beta-cell proliferation and survival for diabetes therapy, as well as inhibiting anti-VEGF drug-induced epithelial-mesenchymal transition (EMT) in retinal pigment epithelium cells. Its biological targets include cell-cycle regulators such as CDK4 and cyclin D1, and it has been shown to modulate CCN2 expression.
- Other names
- CCN5rpCCN-5rpCCN 5rpcellular communication network factor 5Connective tissue growth factor-like proteinConnective tissue growth factor-related protein 58CT58CT-58CT 58CTGF-LCTGFLhrCCN5hrCCN-5hrCCN 5recombinant human CCN5rh-CCN5rh-CCN-5rh-CCN 5rhCCN5rhCCN-5rhCCN 5WISP-2WISP2WISP 2WNT1-inducible-signaling pathway protein 2WNT-1-inducible-signaling pathway protein 2WNT 1-inducible-signaling pathway protein 2
02
Targets
CD9 (CD9 antigen)α6β1 (Integrin alpha-6/beta-1 complex)αVβ3 (Integrin αVβ3)TMSB4X (Thymosin beta-4 X-linked)IGF-1 (Insulin-like growth factor 1)IGF2 (Insulin-like growth factor 2)ITGAV (Integrin αV)ITGB3 (Integrin beta-3)LRP5 (Low-density lipoprotein receptor-related protein 5)LRP6 (Low-density lipoprotein receptor-related protein 6)
Beyond the preview
Go deeper on CCN5 recombinant protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCN5 recombinant protein.